Resources for you and your loved ones
Please refer to the following information to learn about available support and resources.
Support when you need it
Takeda Oncology Support Program is committed to helping patients taking ICLUSIG® (ponatinib) navigate coverage requirements, identify available financial assistance,* and connect with helpful resources throughout their therapy. More details are listed here.
Takeda Oncology Support Program case managers are your connection to personalized support.
Takeda Oncology Support Program can help identify financial assistance programs that may be able to help you with the cost of treatment.
Takeda Oncology Support Program case managers can provide you with information about additional resources that may assist with the day-to-day support you might need.
Support when you need it.
Takeda Oncology Support Program is a comprehensive program committed to helping patients navigate coverage requirements, identify available financial assistance, and connect with helpful resources throughout their therapy.
To learn more, call us today at 1-844-817-6468
If you would like to connect with others who have been affected or learn more about your disease, the organizations listed here may be able to help.
We hope you will use the resources mentioned here to find the people, tools, and education that can help enable you to become an active participant in your care. Takeda Oncology is not affiliated with these organizations. By listing these resources, Takeda Oncology is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided here for informational purposes and are not meant to replace your healthcare provider’s medical advice.
If you have questions about any of the information provided here, please consult with your healthcare provider.
We want you to get the most out of your treatment experience. You can download and print the following resource for additional support.ICLUSIG Patient Guide >>
Click here for
full Prescribing Information
including Boxed Warnings.
Your healthcare provider can help answer any questions you may have about these resources. Please consult with your healthcare provider as soon as you need to.
Accelerated phase CML (AP-CML): The second phase of CML progression, when the number of blast cells is increased.
BCR-ABL1: An abnormal protein that is made by the BCR-ABL1 fusion gene and causes too many abnormal white blood cells (leukemia cells) to be made.
BCR-ABL1 mutations: Changes to the BCR-ABL1 protein that prevent certain TKIs from working.
Blast cell: Abnormal, immature blood cell.
Blast phase CML (BP-CML): The third and final phase of CML progression, which has the highest number of blast cells in the blood and bone marrow and can be life-threatening.
Chemotherapy: Medicines that kill fast-growing cells, including cancer cells and normal cells.
Chronic myeloid leukemia (CML): Form of cancer of the blood-forming cells in the bone marrow that grows slowly and causes too many white blood cells to form.
Chronic phase CML (CP-CML): The first phase of CML, when there are more white blood cells than normal but may not cause symptoms.
Clinical trial: Research on a test or treatment to assess its safety or how well it works.
Complete cytogenetic response (CCyR): Treatment response when no Ph chromosomes are seen in a bone marrow sample.
Complete hematologic response (CHR): Treatment response when blood cell counts decrease to normal and no young abnormal blood cells are seen in the blood.
Complete molecular response (CMR): Treatment response when BCR-ABL1 cannot be detected in the blood.
Complete remission: When no leukemia cells are found in the blood or bone marrow and all signs and symptoms of the cancer are gone.
Corticosteroids: Medicines used to reduce redness, swelling, and pain, but also to kill leukemia cells; also called steroids.
Cytogenetic testing: A test used to look for changes in chromosomes (the part of the cell that contains genetic information).
Deoxyribonucleic acid (DNA): The genetic information carried by cells.
Early molecular response (EMR): Treatment response when BCR-ABL1 levels decrease to ≤10% within 3 to 6 months of starting treatment.
International Scale (IS): A standardized scale for measuring and reporting results of a very sensitive test that measures the number of cells that have the BCR-ABL1 gene.
Intolerance: When treatment with a drug must be stopped because of side effects.
Major cytogenetic response (MCyR): Treatment response when about one-third (35% or less) of cells have the Ph chromosome.
Major hematologic response (MaHR): Treatment response that is either a complete hematologic response or another type of hematologic response called no evidence of leukemia (NEL).
Major molecular response (MMR): Treatment response when BCR-ABL1 levels decrease to <0.1% by 18 months.
Minimal residual disease (MRD): A very small amount of cancer cells left in the body after treatment.
Molecular monitoring: A very sensitive test that can measure very small amounts of BCR-ABL1 in the blood; sometimes referred to as QPCR.
Mutation: Abnormal change in a cell's genetic material (DNA).
Mutation testing: Tests used to see if samples of deoxyribonucleic acid (DNA; the genetic information carried by cells) have changed (mutated).
Partial cytogenetic response (PCyR): Treatment response when 1% to 35% of bone marrow cells still have the Ph chromosome.
Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): Form of leukemia where the cells contain the abnormal Philadelphia chromosome.
Philadelphia (Ph) chromosome: An abnormal chromosome that forms when pieces of chromosomes 9 and 22 switch places with each other. This forms a longer chromosome 9 and a shorter chromosome 22. The shorter chromosome 22 contains the BCR-ABL1 gene and is known as the Philadelphia chromosome.
Quantitative reverse transcriptase polymerase chain reaction (QPCR): A very sensitive test that measures the number of cells in the blood or bone marrow that have BCR-ABL1.
QT prolongation: Electrical signals that help the heart pump are slowed, causing the heart to pump inefficiently.
Resistance (or resistant): When cancer cells do not respond to a treatment.
Stem cell transplant: Treatment that replaces damaged or diseased cells in the bone marrow—soft tissue in the center of bones where blood cells are made—with healthy blood-forming cells called blood stem cells.
T315I: A type of BCR-ABL1 mutation that causes cancer cells to not respond to certain TKIs.
Tyrosine kinase inhibitor (TKI): A type of medicine that stops the growth of leukemic cells by blocking BCR-ABL1.